Theriva Biologics Advances VCN-01 Dosing Trial for Metastatic Pancreatic Cancer
Event summary
- Theriva Biologics received regulatory authorization from AEMPS to initiate the VIRAGE2 Phase 2a clinical trial for VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma patients.
- The trial will evaluate the safety and feasibility of administering at least three doses of VCN-01 two months apart, combined with standard-of-care chemotherapy.
- VIRAGE2 builds on positive data from the VIRAGE Phase 2b trial, where repeated dosing of VCN-01 showed improved overall survival and progression-free survival.
The big picture
Theriva Biologics' VIRAGE2 trial represents a strategic pivot toward optimizing the dosing regimen of its lead candidate, VCN-01, in one of the most aggressive and difficult-to-treat cancers. The move aligns with broader industry trends toward personalized oncology treatments and combination therapies that enhance tumor response. Success in this exploratory study could position Theriva Biologics as a key player in metastatic pancreatic cancer treatment, an area with significant unmet medical need.
What we're watching
- Clinical Efficacy
- Whether more frequent dosing of VCN-01 will demonstrate improved clinical outcomes in future pivotal Phase 3 trials.
- Regulatory Pathway
- The pace at which Theriva Biologics can secure additional regulatory approvals for expanded VCN-01 dosing regimens.
- Commercial Strategy
- How Theriva Biologics plans to leverage VIRAGE2 data to attract potential partners or investors for VCN-01 development.